Aureon Laboratories is developing predictive and personalized cancer treatment options. Aureon employs a unique ‘systems pathology’ approach to provide personalized test results by analyzing a patient’s existing biopsy sample using molecular diagnostics, tissue-based image analysis and mathematics.
Prostate Px, Aureon’s principal product, provides objective analysis of the patient’s biopsy tissue, enabling more-informed, actionable decisions prior to prostate cancer treatment.